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Background-—High-sensitivity troponin (hs-TNT), a biomarker of myocardial damage, might be useful for assessing fibrosis in Fabry
cardiomyopathy. We performed a prospective analysis of hs-TNT as a biomarker for myocardial changes in Fabry patients and a
retrospective longitudinal follow-up study to assess longitudinal hs-TNT changes relative to fibrosis and cardiomyopathy
progression.
Methods and Results-—For the prospective analysis, hs-TNT from 75 consecutive patients with genetically confirmed Fabry
disease was analyzed relative to typical Fabry-associated echocardiographic findings and total myocardial fibrosis as measured by
late gadolinium enhancement (LE) on magnetic resonance imaging. Longitudinal data (3.92.0 years), including hs-TNT, LE, and
echocardiographic findings from 58 Fabry patients, were retrospectively collected. Hs-TNT level positively correlated with LE (linear
correlation coefficient, 0.72; odds ratio, 32.81 [95% CI, 3.56–302.59]; P=0.002); patients with elevated baseline hs-TNT (>14 ng/
L) showed significantly increased LE (median: baseline, 1.9 [1.1–3.3] %; follow-up, 3.2 [2.3–4.9] %; P<0.001) and slightly elevated
hs-TNT (baseline, 44.7 [30.1–65.3] ng/L; follow-up, 49.1 [27.6–69.5] ng/L; P=0.116) during follow-up. Left ventricular wall
thickness and EF of patients with elevated hs-TNT were decreased during follow-up, indicating potential cardiomyopathy
progression.
Conclusions-—hs-TNT is an accurate, easily accessible clinical blood biomarker for detecting replacement fibrosis in patients with
Fabry disease and a qualified predictor of cardiomyopathy progression. Thus, hs-TNT could be helpful for staging and follow-up of
Fabry patients. ( J Am Heart Assoc. 2016;5:e002839 doi: 10.1161/JAHA.115.002839)
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F abry disease (FD) is a rare X-linked lysosomal storagedisorder caused by a mutation in the gene encoding
hydrolase alpha-galactosidase A, leading to a deficiency of
this enzyme. The consequence is a progressive intracellular
accumulation of globotriaosylceramide (Gb3) in lysosomes of
various tissues and organs. The most commonly affected
organs are heart, vascular endothelium of the kidney, nervous
system, eyes, and skin.1–3 Typical clinical manifestations of
FD include angiokeratoma, hypohydrosis, acroparesthesia,
pain crises, and gastrointestinal symptoms such as diarrhea.
Progressive Gb3 accumulation in the microvasculature causes
ischemic damages, especially affecting the kidney, brain, and
heart, which may cause symptoms related to renal failure,
stroke, and cardiovascular diseases.4 Cardiac manifestations,
including arrhythmias, chronic heart failure, and small vessel
disease, occur frequently. Storage of Gb3 in myocytes causes
a regional concentric left ventricular (LV) hypertrophy (LVH)
and results in intramural replacement fibrosis, first limited to
the mid-myocardial layers of the posterolateral wall and then
spreading to transmural fibrosis.5–8 This myocardial fibrosis is
a typical finding of more-advanced stages of Fabry cardiomy-
opathy5,6 and seems to be a major factor in cardiac
arrhythmias and heart failure, which increase morbidity and
reduce life expectancy.5,7,9–11 The most reliable noninvasive
method of detecting myocardial fibrosis is by late gadolinium-
enhanced (LE) magnetic resonance imaging (MRI).6,12
Biomarkers such as cardiac troponin T (TNT) and brain
natriuretic peptide (BNP) are established in the diagnosis of
myocardial infarction (MI) and chronic heart failure,13–16 and
high-sensitivity (hs) TNT has been used to detect myocardial
tissue damage. To date, however, no detailed study has
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assessed the use of biomarkers to detect myocyte turnover
toward myocardial fibrosis in patients with FD. We hypoth-
esized that level of hs-TNT correlates with myocardial fibrosis
and investigated biomarkers, such as hs-TNT and N-terminal
proBNP (NT-proBNP), subsequently correlating the findings
with myocardial fibrosis as measured by LE MRI.
Methods
Study Protocol
The present study comprises 2 analyses: a prospective
analysis to evaluate the relevance of biomarkers such as hs-
TNT and NT-proBNP for detecting myocardial changes in Fabry
patients and a retrospective longitudinal follow-up study to
evaluate longitudinal changes in hs-TNT in relation to fibrosis,
investigate the impact of hs-TNT on progression of cardiomy-
opathy, and evaluate the use of frozen blood for measuring hs-
TNT.
For the prospective part of the study, all patients with
genetically confirmed FD who were observed between
February 2013 and June 2014 at the Fabry center in
Wuerzburg were screened. Criteria for inclusion were (1)
genetically proven FD, (2) availability of blood samples for
measurement of hs-TNT and NT-proBNP, (3) no contraindica-
tions to contrast agent-enhanced MRI, and (4) informed
consent for examination and participation in the study.
Exclusion criteria were contraindications to LE- MRI, such as
claustrophobia, an implanted cardiac pacemaker, or end-stage
renal dysfunction requiring chronic dialysis. Overall, 75
patients were included for the prospective analyses. In the
context of a routine appointment as part of a clinical
investigation program for Fabry patients, blood was taken
and analyzed for hs-TNT and NT-proBNP. To evaluate the
stage of Fabry cardiomyopathy, MRI with LE and echocardio-
graphy were performed within 24 hours. Typical Fabry-related
parameters, symptoms, and comorbidities were determined
by patient interviews and clinical record. A clinical examina-
tion was done by a doctor specialized in FD. In addition, 24-
hour urine samples were collected.
The retrospective cohort consisted of 58 Fabry patients for
whom frozen blood samples were available for assessment of
hs-TNT, as were patient records of MRI and echocardiography
at baseline and after 3.92.0 years.
For the analyses, we separated the cohorts into 4 groups
according to stage of cardiomyopathy, depending on myocar-
dial fibrosis as measured by LE imaging and LVH and
myocardial function as assessed by echocardiography, as
follows: group 1, no cardiomyopathy, meaning no LE findings,
no LVH (interventricular septal thickness at diastole [IVSd]
<12 mm), and normal ejection fraction (EF; ≥55%); group 2,
mild cardiomyopathy, consisting of LV hypertrophy (IVSd
≥12 mm) but no LE and normal EF (≥55%); group 3,
intermediate cardiomyopathy, consisting of patients who
were LE positive but had normal EF (≥55%); and group 4,
end-stage cardiomyopathy, with reduced EF (<55%) and with
fibrosis (LE positive).
Written informed consent was obtained from all patients or
their guardians. The study was approved by the Local Ethics
Committee at the University of W€urzburg and conducted in
accord to the Declaration of Helsinki.
Assessment of hs-TNT and NT-proBNP
All serum concentrations of hs-TNT and NT-proBNP were
measured in the laboratory of the Wuerzburg University
Hospital using the Novel Electrochemiluminescence (ECL)
technology on Roche Cobas e411 (Roche Diagnostics GmbH,
Mannheim, Germany). Peripheral venous blood was taken
from our cohort collected in serum tubes. In the prospective
part of this study, fresh blood samples were immediately
centrifuged at 50009U/min for 10 minutes; afterward,
serum was analyzed within 1 hour. For the retrospective
part, frozen serum was used to measure the level of the
biomarkers. In this cohort, the blood samples were taken, at
their first visit to our Fabry center (baseline) and at a follow-up
visit at the latest time point possible. Serum tubes were also
centrifuged at 50009U/min for 10 minutes, divided into
aliquots, and stored at 80°C until analysis. After defrosting
at room temperature to around 20°C degrees, samples were
again centrifuged at 50009U/min for 10 minutes and
analyzed. The reference ranges for hs-TNT were as follows:
<5 ng/L, below the detection limit; 5 to 13.9 ng/L,
detectable but normal; and ≥14 ng/L, elevated.17,18
N-terminal of the prohormone brain natriuretic peptide (NT-
proBNP) was applied as a “rule-out” test for heart failure. Cut-
off values were based on the recommendations by previous
studies in acute and chronic health care settings (acute heart
failure, 300 pg/mL; chronic heart failure: <60 years, 50 pg/
mL; 60–75 years, 100 pg/mL; >75 years, 250 pg/mL).19,20
Standard Echocardiographic Measurements
All echocardiographic examinations were performed using
standard ultrasound equipment (3.5 MHz; GE VingMed Vivid
7; GE VingMed, Horten, Norway). LV end-diastolic diameter
(LVEDD), LV end-systolic diameter (LVESD), and end-diastolic
wall thickness of the LV posterior wall (LVPWd) and the
septum (IVSd) were manually measured from parasternal
long-axis images using standard M-mode. Furthermore, left
atrial diameter was measured, and the LV fraction shortening
was calculated from LVEDD and LVESD. LV ejection fraction
(LVEF) was measured with the biplane Simpson method
in apical 4- and 2-chamber views. By placing a blood
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pool–pulsed Doppler between the tips of the mitral valve
leaflets, the peak in early (E) and late (A) diastolic flow velocity
was measured, to yield the E/A ratio, and the deceleration
time was extracted. Another parameter to evaluate diastolic
function was the ratio of mitral peak velocity (E/E0) calculated
by measuring the ratio between early transmitral flow and
peak early tissue Doppler velocity. LV mass, indexed to body
surface area (LVMI), was estimated by LV cavity dimension
and wall thickness at end diastole: LV mass (g)=0.89[1.049
(LVEDD+LVPWd+IVSd)3LVEDD3]+0.6. Systolic pulmonary
artery pressure (SPAP) was derived from peak tricuspid
regurgitation (TR) jet velocity, using the simplified Bernoulli
equation in combination with an estimated right atrial
pressure (RAP): SPAP=4V2+RAP, where V is the peak TR jet
velocity. RAP was estimated from inferior vena cava diameter
and respiratory changes.
Assessment of Fibrosis
Cardiac MRI was performed in all patients using a 1.5 Tesla
scanner (Magnetom Symphony Quantum; Siemens Medical
Systems, Erlangen, Germany), after intravenous injection of
gadopentetate dimeglumine 0.2 mmol/kg (Magnevist; Bayer
HealthCare AG, Leverkusen, Germany). LE images were
obtained with T1 inversion recovery sequences (8-mm slice
thickness, breath hold, field of view 2409320 mm2, matrix
size 1659256, repetition time 7.5 ms, echo time 3.4 ms, and
flip angle 258). Areas with pathological mid- or transmural LE
were measured manually in the basal, mid, and apical
segments, covering the entire ventricle using continuous
short-axis views. The sum of all enhanced areas was
multiplied by the slice thickness and then set in relation to
the LV myocardial volume. With this technique, every LV
segment was scanned separately for occurrence of patholog-
ical LE. Attention was paid to a similar setting for the follow-
up scan.
Statistical Analysis
Continuous data are presented as meanSD or median (25th,
75th percentiles) and categorical variables as numbers
(percentages). Differences in continuous data among 3 groups
were compared using 1-way ANOVA after normalization, if
indicated, followed by appropriate post-hoc tests for multiple
comparisons (Tukey’s if equal variances assumed; Games-
Howell if equal variances not assumed). Pair-wise compar-
isons were only conducted if the global test was significant.
Statistical significance was assumed at Bonferroni-adjusted
P<0.025 (3 groups). Differences between baseline and follow
up among 3 groups were compared using repeated-measures
ANOVA followed by the appropriate post-hoc test for multiple
comparisons. Non-normally distributed variables (hs-TNT and
NT-proBNP) were normalized before analysis using natural
logarithm values (Ln). Correlation between hs-TNT categories
and other clinical and echocardiographic parameters were
studied with the Spearman rank correlation (rs). The differ-
ence between groups was compared using independent-
samples t test. Categorical data were compared across
groups using the chi-square test. Logistic regression was used
to assess significant determinants of elevated hs-TNT.
A P<0.05 (2 groups) was considered statistically significant,
and all statistical analysis was performed using IBM SPSS
software (version 22 for Windows; SPSS, Inc., Chicago, IL).
Results
Prospective Cohort
Our prospective cohort of 75 patients with a mean age of
4314 years included 47 women and 28 men. Average body
mass index (BMI) was normal (mean 255 kg/m2). No
patient had a history of MI, only 1 patient had undergone a
coronary bypass operation, and 3 patients had coronary artery
disease (CAD). Three patients had chronic heart failure
corresponding with New York Heart Association (NYHA) class
III or IV. Mean glomerular filtration rate (GFR) was in normal
range (8323 mL/min), 29.3% (n=22) of patients had
proteinuria, 84.2% had normal renal function, 7.9% (n=6)
had a moderately reduced kidney function (stage III of chronic
kidney disease [CKD], GFR between 30 and 59 mL/min), and
4.0% (n=3) had severely reduced kidney function (stage IV of
CKD, GFR 15–29 mL/min). Patients with end-stage renal
disease (ESRD; 1.33%; n=1) were excluded.
The median hs-TNT of the cohort was 7.7 ng/L, with a
wide range of 4 to 278 ng/L. Of the 75 patients, 30 (40%) had
an elevated hs-TNT (>14 ng/L). The general clinical data for
all patients adjusted to the level of hs-TNT (<5, 5–14, and
>14 ng/L) are presented in Table 1. Of note are some
correlations between level of hs-TNT and other typical Fabry
symptoms.
Separation of the cohort into the stages of Fabry
cardiomyopathy according to the above-mentioned criteria
resulted in 38 patients with no cardiomyopathy, 3 with mild
cardiomyopathy, 31 with intermediate cardiomyopathy, and 3
with end-stage cardiomyopathy (Figure 1). Patients with no or
mild cardiomyopathy had low levels of hs-TNT, whereas those
with intermediate and end-stage cardiomyopathy had ele-
vated levels (Figure 1).
Table 2 shows echocardiographic and MRI characteristics
of the prospective cohort. LV wall thickness, LVMI on
echocardiography, and MRI, E/E0, and LE-positive myocardial
volume gradually increased with increasing hs-TNT. All but 1
patient (97%) with an elevated hs-TNT >14 ng/L showed
fibrosis as assessed by LE on MRI.
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Table 1. Clinical Characteristics Among Subgroups According to hs-TNT Level in the Prospective Cohort (n=75)
Total hs-TNT <5 ng/L hs-TNT 5 to 14 ng/L hs-TNT >14 ng/L
n=75 n=29 n=16 n=30
Age, y 4314 4513 4112 4315
Female, n (%) 47 (62.7) 19 (65.5) 12 (75) 16 (53.3)
BMI, kg/m² 255 244 254 256
hs-TNT*, ng/L 7.7 (4–20.8) 4 7.7 (6.7–8.4)† 24.2 (19.1–44.1)†‡
NT-proBNP*, pg/mL 99 (41–224) 49.5 (28.5–77.5) 80.5 (33.5–153.5) 221 (106–910)†‡
Cardiovascular, n (%)
NYHA class III/IV 3 (4.0) 1 (3.4) 0 (0) 2 (6.7)
CAD 3 (4.0) 0 0 3 (10.0)
MI 0 0 0 0
Bypass 1 (1.3) 0 0 1 (3.3)
ICD/pacemaker 7 (6.7) 0 0 5 (16.7)†‡
Renal
eGFR, mL/min 8323 9722 8018† 7019†
Creatinine, mg/dL 1.00.3 0.80.2 0.90.2 1.10.3†
Proteinuria, n (%) 22 (29.3) 6 (20.7) 2 (12.5) 14 (46.7)†‡
Renal insufficiency:
0/I/II/III/IV, %
64/0/2/6/3
(84.2/0/2.6/7.9/4.0)
28/0/1/0/0
(96.6/0/3.4/0/0)
14/0/0/2/0
(87.5/0/0/12.5/0)
22/0/1/4/3
(71/0/3.2/12.9/10.0)
Renal transplantation, n (%) 3 (4.0) 0 0 3 (10.0)
Neurological, n (%)
Vertigo 37 (49.3) 11 (37.9) 10 (62.5) 16 (53.3)
Tinnitus 24 (32.0) 5 (17.2) 4 (25.0) 15 (50)†
Hearing loss 11 (14.7) 1 (3.4) 3 (18.8) 7 (23.3)
Depression 7 (9.3) 2 (6.9) 2 (12.5) 3 (10.0)
Dysarthria 6 (8.0) 2 (6.9) 1 (6.3) 3 (10.0)
TIA 6 (8.0) 3 (10.3) 1 (6.3) 2 (6.7)
Stroke 7 (9.3) 1 (3.4) 1 (6.3) 5 (16.7)
Gastrointestinal, n (%)
Nausea 7 (9.3) 3 (10.3) 1 (6.3) 3 (10.0)
Diarrhea 24 (32.0) 5 (17.2) 5 (31.3) 14 (46.7)
Abdominal pain 21 (28.0) 5 (17.2) 5 (31.3) 11 (36.7)
Acroparesthesia, n (%) 43 (57.3) 16 (55.2) 8 (50) 19 (63.3)
Chronic pain, n (%) 20 (26.7) 8 (27.6) 2 (12.5) 10 (33.3)
Pain crisis, n (%) 24 (32.0) 10 (34.5) 3 (18.8) 11 (36.7)
Medication, n (%)
ACE/AT1 46 (61.3) 8 (27.6) 12 (75)† 26 (86.7)†
ß-blockers 10 (13.3) 3 (10.3) 2 (12.5) 5 (16.7)
Calcium antagonists 3 (4.0) 1 (3.4) 0 (0) 2 (6.7)
Anticoagulant 4 (5.3) 0 0 4 (13.3)
Regular pain medication 13 (17.3) 6 (20.7) 1 (6.3) 6 (20.0)
ACE indicates angiotensin-converting enzyme inhibitor; AT1, angiotensin II type 1 antagonists; BMI, body mass index; CAD, coronary arterial disease; eGFR, estimated glomerular filtration
rate; hs-TNT, high-sensitivity cardiac troponin T; ICD, implantable cardioverter-defibrillator; MI, myocardial infarction; NT-proBNP, N-terminal of the prohormone brain natriuretic peptide;
NYHA, New York Heart Association; TIA, transient ischemic attack.
*Natural logarithm (Ln) transformed.
Bonferroni-adjusted †P<0.025 vs hs-TNT <5 ng/L; ‡P<0.025 vs hs-TNT 5 to 14 ng/L.
DOI: 10.1161/JAHA.115.002839 Journal of the American Heart Association 4
High-Sensitivity Troponin in Fabry Seydelmann et al
O
R
IG
IN
A
L
R
E
S
E
A
R
C
H
D
ow
nloaded from
 http://ahajournals.org by on June 9, 2020
Correlation analysis showed that hs-TNT categories posi-
tively correlated with NYHA functional class, NT-proBNP,
creatinine, LE-positive myocardial volume, LV wall thickness,
LVMI, LA diameter, and E/E0 and negatively correlated with
estimated GFR (eGFR; Table 3). Multivariable logistic regres-
sion analysis suggested that only LE-positive myocardial
volume was independently associated with hs-TNT elevation
(Table 4; odds ratio [OR], 32.81; 95% CI, 3.56–302.59;
P=0.002). Comparison of hs-TNT with LVH (septal wall
thickness, R2 linear=0.58; r=0.76; P<0.001; Figure 2A) and
amount of LV fibrosis (LE-positive myocardial volume, R2
linear=0.66; r=0.72; P<0.001; Figure 2B) showed a strong
positive correlation. A moderate positive correlation also was
noted between NT-proBNP level and amount of LV fibrosis (R2
linear=0.22; r=0.66; P<0.001; Figure 2C).
A closer look at patients with renal insufficiency showed
that CKD stage III to IV was more frequently present in
patients with hs-TNT >14 ng/L compared to those with hs-
TNT <5 and 5 to 14 ng/L. Advanced kidney dysfunction was
significantly associated with an elevated hs-TNT level (median:
Figure 1. High-sensitivity cardiac troponin T (hs-TNT) levels in Fabry patients with different stages of
cardiomyopathy (CM). Box plots represent median levels with 25th and 75th percentiles of observed data
whereas whiskers indicate the 5th and 95th percentiles in each group. The y-axis ranges from 1 to 6
representing natural logarithm values of hs-TNT (Ln hs-TNT). EF indicates ejection fraction; IVSd, end-
diastolic interventricular septal wall thicknes; LE, late enhancement; LV, left ventricle.
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CKD stage III–IV, 32.7 [18.6–44.1] ng/L vs stage 0–II, 6.7 [4–
19.2] ng/L; P=0.003). There was a strong correlation between
hs-TNT and LE-positive myocardial volume both in patients
with CKD stage I to II (n=66; r=0.805; P<0.001) and in
patients with stage III to IV (n=9; r=0.797; P=0.010).
Longitudinal, Retrospective Data
For follow-up, 58 patients were screened for hs-TNT, NT-
proBNP, and typical features of Fabry cardiomyopathy on MRI
and echocardiography at baseline and at the latest possible
time. As shown in Table 5, over a follow-up period of
3.92.0 years, patients with an elevated hs-TNT (>14 ng/L)
at baseline had significantly increasing replacement fibrosis
(median: baseline, 1.9 [1.1–3.3] %; follow-up, 3.2 [2.3–4.9] %;
P<0.001) and slightly increasing hs-TNT (baseline, 44.7 [30.1–
65.3] ng/L; follow-up, 49.1 [27.6–69.5] ng/L; P=0.116). In
addition, LV wall thickness of patients with elevated hs-TNT
was significantly decreased (baseline, 14.53.1 mm; follow-
up, 13.72.3 mm; P=0.043) and EF tended to be reduced
(baseline, 666%; follow-up, 638%; P>0.05) during follow-
up. LV wall thickness thinning might be associated with
intramural replacement fibrosis and progression of heart
failure and usually occurs in the late stage of disease.21 Global
systolic function (=EF) in patients with elevated hs-TNT was
decreased during follow-up, indicating potential cardiomyopa-
thy progression as well.
Of the 58 patients with longitudinal data, 21 (36.2%)
underwent enzyme replacement therapy (ERT). As shown in
Table 6, patients in the ERT group had higher hs-TNT levels
and thicker LV wall thickness compared to the no-ERT group
at baseline. LE-positive myocardial volume was similar
Table 2. Echocardiography and Cardiac Magnetic Resonance Imaging in the Prospective Cohort (n=75)
Total hs-TNT <5 ng/L hs-TNT 5 to 14 ng/L hs-TNT >14 ng/L
n=75 n=29 n=16 n=30
Echocardiography
LV end-diastolic dimension, mm 476 475 456 487
IVSd, mm 10.22.5 8.21.4 9.91.7* 12.22.1*†
LVPWd, mm 10.02.3 8.31.3 9.81.5* 11.72.1*†
LV fractional shortening, mm 367 358 396 356
End-diastolic LV volume, mL 10732 11022 9328 11139
End-systolic LV volume, mL 3818 4015 3012 4121
Stroke volume, mL 6921 6917 6421 7126
LV mass index, g/m² 9643 9138 9636 10251
Left atrial diameter, mm 355 334 353 385*†
LVEF, % 656 646 656 666
E/A 1.50.6 1.50.5 1.40.5 1.60.7
E/E0 10.44.6 7.01.8 9.72.6* 13.94.8*†
DT, ms 20849 20156 20737 21649
SPAP, mm Hg 256 245 255 277
Magnetic resonance imaging
LE positive, n (%) 34 (45.3) 1 (3.4) 4 (25.0) 29 (96.7)
LE-positive myocardial volume, % 0 (0–8.5) 0 (0–0.71) 0 (0–1.2)* 1.4 (0–8.5)*†
LVMI, g/m² 8836 6919 7924 11141*†
End-diastolic LV volume, mL 14245 14037 13031 15057
End-systolic LV volume, mL 5124 5521 3913 5529
Stroke volume, mL 9225 9123 9222 9328
LVEF, % 6610 648 706 6513
DT indicates deceleration time of early filling; E/A, early diastolic filling velocity (E) to late diastolic filling velocity (A) ratio; E/E0 , mitral inflow velocity (E) to tissue Doppler E0 ratio; hs-TNT,
high-sensitivity cardiac troponin T; IVSd, end-diastolic interventricular septal wall thickness; LE, late enhancement; LV, left ventricle; LVEF, LV ejection fraction; LVMI, LV mass indexed to
body surface area; LVPWd, end-diastolic posterior wall thickness; SPAP, systolic pulmonary artery pressure.
*P<0.05 vs hs-TNT <5 ng/L.
†
P<0.05 vs hs-TNT 5 to 14 ng/L.
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between groups at baseline. During follow-up, hs-TNT level
and LE-positive myocardial volumes were significantly
increased in both groups.
Discussion
The aim of this study was to investigate the clinical value of
hs-TNT as a blood biomarker for evaluating myocardial
replacement fibrosis in patients with FD. The main results
are 4-fold: First, the well-known myocyte turnover resulting in
myocardial replacement fibrosis was associated with plasma
hs-TNT elevation. Second, hs-TNT level correlated with the
total amount of replacement fibrosis. Third, elevated hs-TNT
could predict an increase in the extent of fibrosis. Finally, hs-
TNT was very stable and predictive even in frozen blood
stored for more than 5 years.
hs-TNT is a reliable, highly sensitive marker for myocyte
necrosis and myocardial remodeling, both resulting in
myocardial fibrosis.22 Moreno et al. showed that patients
with hypertrophic cardiomyopathy and LE on MRI have
higher levels of hs-TNT than hypertrophic cardiomyopathy
patients without LE.23 In accord with these findings,
Kawasaki et al. demonstrated that higher levels of hs-TNT
are associated with LE on MRI in patients with cardiomy-
opathy and suggested that hs-TNT is therefore a direct
marker for myocardial replacement fibrosis.24 In an initial
study, Feustel et al. showed that regular troponin I was
continuously elevated in 3 patients with a Fabry cardiomy-
opathy.25 However, this troponin I was, by far, not as
sensitive for myocyte turnover as the hs-TNT used in the
current study. To date, no well-performed study has
investigated the association of hs-TNT and replacement
fibrosis in patients with Fabry cardiomyopathy. In the current
work, both the level of hs-TNT and LE-positive area were
quantified, and absolute values were given for both param-
eters in all patients. In this way, we showed a clear
correlation between the blood biomarkers and morphological
finding of replacement fibrosis. However, whether or not the
circulated hs-TNT is finally generated by myocyte turnover in
the LE-positive region remains unclear. It can be speculated
that hs-TNT is generated everywhere in the diseased
myocardium of the LV. If so, then the correlation could
Table 3. Spearman’s Rank Correlation Between hs-TNT
Categories and Clinical and Echocardiographic Variables in
the Prospective Cohort (n=75)
Spearman’s Rank
Correlation Coefficient (rs) P Value
Age, y 0.07 0.57
Sex 0.11 (v²=2.26) 0.33
BMI, kg/m² 0.07 0.56
NYHA class 0.38 (v²=12.97) 0.001
NT-proBNP*, mg/dL 0.55 <0.001
eGFR, mL/min 0.51 <0.001
Creatinine, mg/dL 0.36 0.001
LE-positive myocardial
volume, %
0.82 <0.001
MRI-LVMI, g/m² 0.55 <0.001
Echo-LVMI, g/m² 0.09 0.31
IVSd, mm 0.74 <0.001
LVPWd, mm 0.70 <0.001
LV end-diastolic
dimension, mm
0.05 0.77
EF, % 0.17 0.15
Left atrial diameter, mm 0.44 <0.001
E/e0 0.69 <0.001
DT 0.19 0.10
SPAP 0.20 0.10
BMI indicates body mass index; DT, deceleration time of early filling; E/E0 , mitral inflow
velocity (E) to tissue Doppler E0 ratio; EF, ejection fraction; eGFR, estimated glomerular
filtration rate; hs-TNT, high-sensitivity cardiac troponin T; IVSd, end-diastolic
interventricular septal wall thickness; LE, late enhancement; LV, left ventricle; LVMI, LV
mass indexed to body surface area; LVPWd, end-diastolic posterior wall thickness; NT-
proBNP, N-terminal of the prohormone brain natriuretic peptide; NYHA, New York Heart
Association; SPAP, systolic pulmonary artery pressure.
*Ln-transformed.
Table 4. Determinants of Elevated hs-TNT (>14 ng/L) Assessed by Logistic Regression Analysis in the Prospective Cohort (n=75)
Adjusted* Multivariate*
OR (95% CI) P Value OR (95% CI) P Value
eGFR, mL/min 0.95 (0.92–0.98) 0.001 1.00 (0.94–1.06) 0.946
NT-proBNP†, pg/mL 2.96 (1.71–5.21) <0.001 1.79 (0.59–5.40) 0.304
LE-positive myocardial volume, % 97.2 (12.9–734.1) <0.001 32.81 (3.56–302.59) 0.002
IVSd, mm 2.62 (1.71–4.00) <0.001 2.49 (0.96–6.47) 0.061
Left atrial diameter, mm 1.27 (1.10–1.47) 0.001 1.15 (0.82–1.61) 0.431
eGFR indicates estimated glomerular filtration rate; hs-TNT, high-sensitivity cardiac troponin T; IVSd, end-diastolic interventricular septal wall thickness; LE, late enhancement; NT-proBNP,
N-terminal of the prohormone brain natriuretic peptide; OR, odds ratio.
*Adjusted for age, sex, and body mass index.
†
Ln-transformed.
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result from the fact that the amount of replacement fibrosis
mirrors the severity of the diseased myocardium.
The current study also investigated NT-proBNP as a marker
of cardiomyopathy. NT-proBNP is an established biomarker
for heart failure and is mainly related to the wall stress acting
on the heart.24,26,27 In general, only truly end-stage Fabry
cardiomyopathy patients suffer from heart failure;7,28 in
addition, blood pressure (one of the main components of
wall stress) is not severely elevated in these patients. Thus, it
was predictable that NT-proBNP was only a weak biomarker
for cardiomyopathy and not clinically meaningful in terms of
the amount of fibrosis.
Evaluation of myocardial fibrosis by either imaging or
biomarkers is clinically important because fibrosis defines the
stage of cardiomyopathy, predicts the outcome during ERT,
and indicates a poor prognosis.5,11,29,30 The noninvasive gold
standard for detecting intramural replacement fibrosis is LE
MRI.6 LE imaging is accurate for evaluating the LV and highly
sensitive for detecting and quantifying a small amount of
fibrosis.31–34 However, this technique is expensive, time-
consuming, and often not available for routine diagnosis.
Furthermore, many Fabry patients have contraindications for
undergoing MRI, such as ESRD or an implanted cardiac
defibrillator or pacemaker.31 Another indirect way to screen
for regional myocardial fibrosis is by functional deformation
imaging.27,28 This method is sensitive for detecting systolic
functional abnormalities; however, it requires an experienced
investigator. Additionally, this method is also time-consuming
and not easy to postprocess.30,31,33,35
Clinical Implication
The current data suggest that hs-TNT could be measured in
every Fabry patient at every visit because it is widely available
and not expensive. If it is in normal range, that in combination
with normal echocardiography and 12-lead electrocardiogra-
phy means that a typical Fabry cardiomyopathy is very
unlikely. If the level of hs-TNT is borderline, a sophisticated
search, including cardiac MRI, for replacement fibrosis should
be done. On the other hand, if the level is very high, an
advanced cardiomyopathy is likely present, and imaging of the
fibrosis is necessary only for confirmation. In addition, in
patients with elevated hs-TNT, the progression of the
cardiomyopathy can be anticipated even when these patients
are treated with ERT; thus, a careful follow-up of these
patients should be performed.
Limitations
ESRD patients treated with dialysis were excluded from these
analyses because LE imaging is contraindicated. It is possible
that hs-TNT could, in part, accumulate because of a decreased
Figure 2. Scatterplots demonstrating the correlation of (A) high-
sensitivity cardiac troponin T (hs-TNT) with septal wall thickness
(IVSd, mm); (B) hs-TNT with late enhancement (LE) positive
myocardial volume (%); and (C) NT-proBNP with LE-positive
myocardial volume (%). Natural logarithm (Ln) values of hs-TNT (A
and B) and NT-proBNP (C) are used as the Y-axis scale. NT-proBNP
indicates N-terminal of the prohormone brain natriuretic peptide.
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renal filtration rate; thus, the suggested biomarker should not
be used in hemodialysis patients. In addition, the patient
sample was relatively small for the longitudinal cohort and all
data were retrospectively collected. The duration between
baseline and follow-up examinations was unable to be
standardized. These limitations could have introduced some
bias. Prospective studies with larger sample size are certainly
warranted to validate the current results.
Conclusion
The present study shows a clinically meaningful correlation
between plasma hs-TNT level and the amount of replacement
fibrosis as assessed by LE. These findings indicate that hs-
TNT is a reliable tool for screening for myocardial fibrosis. It is
convenient, cost-effective, easy to determine, and involves
few contraindications. Moreover, hs-TNT can be used as an
easy predictor of the progression of Fabry cardiomyopathy.
Thus, we suggest that the biomarker hs-TNT could be helpful
for staging and follow-up of Fabry patients.
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Table 5. Changes in hs-TNT Level, LE-Positive Myocardium, Cardiac Morphology, and Function During Follow-up (n=58)
hs-TNT <5 ng/L hs-TNT 5 to 14 ng/L hs-TNT >14 ng/L
n=26 n=19 n=13
Duration of follow-up, y 4.61.9 3.62.0 2.91.8†
hs-TNT*, ng/L
Baseline 4.0 8.7 (7.2–10.2)† 44.7 (30.1–65.3)†‡
Follow-up 4.0 (4.0–5.9)§ 12.5 (9.0–18.1)†§ 49.1 (27.6–69.5)†‡
LE-positive myocardial volume, %
Baseline 0 (0–0.3) 0.4 (0–1.6)† 1.9 (1.1–3.3)†‡
Follow-up 0.3 (0–1.4)§ 1.5 (0.4–3.1)†§ 3.2 (2.3–4.9)†‡§
IVSd, mm
Baseline 9.11.1 11.51.7† 14.53.1†‡
Follow-up 9.11.5 11.31.4† 13.72.3†‡§
EF, %
Baseline 645 655 666
Follow-up 636 655 638
Using repeated-measures ANOVA followed by Bonferroni post-hoc test for multiple comparisons. EF indicates ejection fraction; hs-TNT, high-sensitivity cardiac troponin T; IVSd, end-
diastolic interventricular septal wall thickness; LE, late enhancement.
*Ln-transformed.
Bonferroni-adjusted †P<0.025 vs hs-TNT <5 ng/L; ‡P<0.025 vs hs-TNT 5 to 14 ng/L.
§
P<0.05 vs baseline.
Table 6. Changes in hs-TNT Level, LE-Positive Myocardium,
Cardiac Morphology, and Function During Follow-up (n=58) in
Patients With and Without ERT
No ERT ERT
n=37 n=21
hs-TNT*, ng/L
Baseline 4.0 (4.0–10.4) 8.9 (4.8–30.1)†
Follow-up 6.1 (4.0–18.9)‡ 14.6 (6.9–48.0)†‡
LE-positive myocardial volume, %
Baseline 0.2 (0–1.2) 0.6 (0–1.8)
Follow-up 1.0 (0–2.3)‡ 2.3 (0.6–3.9)‡
IVSd, mm
Baseline 10.32.2 12.63.2†
Follow-up 10.12.2 12.12.5†
EF, %
Baseline 655 655
Follow-up 646 627
Using repeated-measures ANOVA followed by Tukey’s post-hoc test. EF indicates
ejection fraction; ERT, enzyme replacement therapy; hs-TNT, high-sensitivity cardiac
troponin T; IVSd, end-diastolic interventricular septal wall thickness; LE, late
enhancement.
*Ln-transformed.
†
P<0.05 vs no ERT.
‡
P<0.05 vs baseline.
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